WO2012110430A1 - Novel composition for topical use on a nail - Google Patents
Novel composition for topical use on a nail Download PDFInfo
- Publication number
- WO2012110430A1 WO2012110430A1 PCT/EP2012/052354 EP2012052354W WO2012110430A1 WO 2012110430 A1 WO2012110430 A1 WO 2012110430A1 EP 2012052354 W EP2012052354 W EP 2012052354W WO 2012110430 A1 WO2012110430 A1 WO 2012110430A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- urea
- composition
- lactic acid
- composition according
- ethyl acetate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 164
- 230000000699 topical effect Effects 0.000 title claims abstract description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 259
- 239000004202 carbamide Substances 0.000 claims abstract description 138
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 138
- 239000004310 lactic acid Substances 0.000 claims abstract description 69
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 69
- 150000002009 diols Chemical class 0.000 claims abstract description 38
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 8
- 239000012669 liquid formulation Substances 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 171
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 171
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 78
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 49
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 49
- 239000003349 gelling agent Substances 0.000 claims description 27
- 239000002562 thickening agent Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 16
- 229940121375 antifungal agent Drugs 0.000 claims description 15
- 239000002738 chelating agent Substances 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 12
- 239000003429 antifungal agent Substances 0.000 claims description 10
- 230000008020 evaporation Effects 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 3
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 3
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 3
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 3
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 3
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 3
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 3
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 3
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 claims description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- 108010064760 Anidulafungin Proteins 0.000 claims description 3
- 108010020326 Caspofungin Proteins 0.000 claims description 3
- 108010049047 Echinocandins Proteins 0.000 claims description 3
- 108010021062 Micafungin Proteins 0.000 claims description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 3
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 claims description 3
- 229950006373 abafungin Drugs 0.000 claims description 3
- 229960003204 amorolfine Drugs 0.000 claims description 3
- 229960003348 anidulafungin Drugs 0.000 claims description 3
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 claims description 3
- 229960002206 bifonazole Drugs 0.000 claims description 3
- 229960002962 butenafine Drugs 0.000 claims description 3
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims description 3
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005074 butoconazole Drugs 0.000 claims description 3
- 229960003034 caspofungin Drugs 0.000 claims description 3
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 3
- 229960003913 econazole Drugs 0.000 claims description 3
- 229960001274 fenticonazole Drugs 0.000 claims description 3
- 229960004884 fluconazole Drugs 0.000 claims description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 claims description 3
- 229960000788 isavuconazole Drugs 0.000 claims description 3
- 229960004849 isoconazole Drugs 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 229960002159 micafungin Drugs 0.000 claims description 3
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 claims description 3
- 229960002509 miconazole Drugs 0.000 claims description 3
- 229960004313 naftifine Drugs 0.000 claims description 3
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 3
- 229960003483 oxiconazole Drugs 0.000 claims description 3
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 3
- 229960001589 posaconazole Drugs 0.000 claims description 3
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 claims description 3
- 229950004154 ravuconazole Drugs 0.000 claims description 3
- 229960005429 sertaconazole Drugs 0.000 claims description 3
- 229960002607 sulconazole Drugs 0.000 claims description 3
- 229960002722 terbinafine Drugs 0.000 claims description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 3
- 229960000580 terconazole Drugs 0.000 claims description 3
- 150000003557 thiazoles Chemical class 0.000 claims description 3
- 229960004214 tioconazole Drugs 0.000 claims description 3
- 150000003852 triazoles Chemical class 0.000 claims description 3
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 3
- 229960004740 voriconazole Drugs 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 33
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 24
- 229920000053 polysorbate 80 Polymers 0.000 description 24
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 23
- 229940068968 polysorbate 80 Drugs 0.000 description 23
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 13
- 229920003160 Eudragit® RS PO Polymers 0.000 description 12
- 230000035515 penetration Effects 0.000 description 12
- 210000000003 hoof Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 229920000193 polymethacrylate Polymers 0.000 description 8
- 229920003134 Eudragit® polymer Polymers 0.000 description 7
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 7
- 230000000843 anti-fungal effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000012071 phase Substances 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
- -1 or clotimtrazole Chemical compound 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940116333 ethyl lactate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Definitions
- the present invention generally relates to novel compositions comprising urea for topical application on nails.
- Urea is a useful agent for the treatment of several skin conditions and is often included in formulations for the treatment of nails. Urea can also be used as a penetration enhancer in formulations for skin and can be included in formulations for the treatment of nails.
- US2007/01 96453 (Zars Inc, Zhang Jie et al.) concerns adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug.
- the formulation can include a drug, a solvent vehicle, and a solidifying agent.
- the solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux- enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time.
- the formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system .
- the formulation When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.
- the major degradation products of urea are carbon dioxide and ammonia. Factors that promote the degradation process include light, heat and the presence of certain enzymes.
- formulations comprising urea.
- soluble refers the ability of the solvent to dissolve an amount of the active pharmaceutical ingredient that is relevant for its pharmacological effect.
- a urea-comprising composition for topical application on a nail comprising urea, a diol, lactic acid or an ester thereof, and a volatile vehicle, characterized in that urea is soluble in the composition in the absence of the volatile vehicle, and that urea is in the solid state in the composition in the presence of the volatile vehicle.
- composition is intended for cosmetic and/or pharmaceutical use on discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
- the invention presents a novel way to maximize the chemical activity of urea and thereby the penetration rate through nail and preserving the urea so that it is not degraded.
- the inventive formulations and method minimizes the chemical degradation of urea as the whole composition contains very little water and the urea is in the solid state.
- the invention also results in an increased concentration of urea on the application site when the volatile vehicle evaporates, thereby facilitating penetration. This results in higher penetration of urea.
- composition will have a high stability and therefore a long shelf life.
- the longer shelf-life increases cost-efficiency, as larger batches can be produced, distributed and stored.
- the formulation lacks an antifungal agent, in particular an antifungal agent with strong antifungal activity. This enables the production and sale of a non-prescription product and/or over the counter product.
- the composition does not comprise an antifungal agent selected among imidazoles, triazoles, thiazoles, allylamines, and echinocandins examples of which are miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole,
- an antifungal agent selected among imidazoles, triazoles, thiazoles, allylamines, and echinocandins examples of which are miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, t
- Voriconazole terconazole, abafungin, terbinafine, amorolfine, naftifine, butenafine, anidulafungin, caspofungin, and micafungin .
- the lactic acid or ester thereof may be lactic acid.
- the diol in the composition is preferably propylene glycol.
- the volatile vehicle comprises, consists essentially of, or consists of, at least one selected from the group consisting of ethyl acetate and butyl acetate and mixtures of ethyl acetate and butyl acetate.
- One suitable composition comprises from 2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof and from 0.5% to 8% of urea and from 55% to 95% of a volatile vehicle.
- Another suitable composition comprises from 2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof, from 0.5% to 8% of urea; the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate, and optionally, other components selected from the group consisting of a gelling agent or thickener, a surfactant, a chelating agent, sodium hydroxide, water and glycerol.
- compositions consist- or consist essentially of - from 2.5% to 32% of propylene glycol, from 0.25% to 6% of lactic acid, from 0.5% to 8% of urea, from 0.05% to 1 .5% of a surfactant; from 0. 1 % to 1 % of a chelating agent, from 2% to 1 6% of a gelling agent or thickener, from 0.01 % to 0.8% of sodium hydroxide and from 0. 1 % to 1 % of water and from 1 % to 5% of glycerol; the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
- compositions for use in the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis are provided.
- composition according to the invention for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
- a method for increasing the stability of urea comprises the steps of dissolving urea in a solvent comprising a diol and lactic acid and adding a volatile vehicle which precipitates the urea.
- a method for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis comprising the step of topically administering a composition according to the invention on a nail.
- the method comprises the steps of applying the inventive composition to a nail, allowing the volatile vehicle to evaporate so that urea dissolves in the remaining solvents, and leaving the composition on the nail and allowing the urea exert its function.
- the amount of urea present in the composition after evaporation of the volatile vehicle is from 2% to 30%.
- the application is carried out at least once a week.
- composition comprising a precipitation or suspension of urea obtainable according to the method described herein .
- the composition comprises a suspension of urea particles in a solvent comprising a diol and lactic acid or an ester thereof and a volatile vehicle that precipitates urea.
- the solvent has a lower vapor pressure than the volatile vehicle such that the composition comprises a suspension of urea particles during storage when the volatile vehicle is present.
- the volatile vehicle evaporates.
- the urea dissolves in the remaining components (mainly lactic acid and a diol), so that it becomes accessible for penetration into the nail.
- At least 30%, more preferably at least 50%, more preferably at least 60% and most preferably at least 70% of the urea is solu the composition in the absence of the volatile vehicle.
- the composition includes lactic acid or an ester thereof. Suitable esters of lactic acid include butyl lactate and ethyl lactate. Mixtures of two or more of lactic acid, butyl lactate and ethyl lactate are also suitable.
- the disclosed formulation allows high penetration of urea to, through and into the nail.
- At least 5%, more preferably at least 1 0%, more preferably at least 20%, more preferably 30%, more preferably 40% more preferably 50%, more preferably 60 %, more preferably 80% and most preferably at least 95% of the urea is in the solid state in the presence of the volatile vehicle at a temperature from 2°C to 25°C.
- composition does not comprise an antifungal agent, that is, a compound with strong antifungal activity.
- an antifungal agent that is, a compound with strong antifungal activity.
- a list of such antifungals can be found in Goodman & Gilmans The pharmacological basis of therapeutics, 2001 , 1 295- 1 3 1 2, McGraw-Hill.
- the composition does not comprise imidazoles, such as miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazoles, such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, and terconazole; thiazoles, such as abafungin; allylamines, such as terbinafine, amorolfine, naftifine, and butenafine; and echinocandins, such as anidulafungin, caspofungin, and micafungin .
- imidazoles such as miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole
- composition does not comprise polyenes or miscellaneous compounds such as griseofulvin, benzoic, salicylic, propionic, undecylenic or caprylic acid, or clotimtrazole, potassium iodide, tolnaphtate, ciclopirox olamine, amphotercin C, nystatin, flucytosine, or haloprogine.
- polyenes or miscellaneous compounds such as griseofulvin, benzoic, salicylic, propionic, undecylenic or caprylic acid, or clotimtrazole, potassium iodide, tolnaphtate, ciclopirox olamine, amphotercin C, nystatin, flucytosine, or haloprogine.
- one further advantage is that the formulation lacks an antifungal agent with strong antifungal activity. This enables the production and marketing of a product that can be sold as a non-prescription and/or over-the-counter product. Furthermore, the use of antifungal drugs will cause antifungal agents to be released to the environment. The use of antifungals may result in the development of resistance to these drugs which would result in reduced efficacy of available treatment. One further aspect is that antifungal drugs are expensive to produce and handle. All of these drawbacks are avoided by excluding an antifungal drug.
- the amount of urea present in the invented composition after evaporation of the volatile vehicle is in the range of from 2% to 40%, more preferably from 2% to 30%.
- the amount of diol, preferably propylene glycol, in the composition after evaporation of the volatile part is preferably from 40% to 90%.
- the composition comprises a diol, of which in particular propylene glycol is suitable.
- a diol of which in particular propylene glycol is suitable.
- Other suitable diols are butanediol, pentanediol and hexanediol.
- the combined amount of urea, diol and lactic acid in the composition is preferably from about 5% to about 40% of the total composition, more preferably from 1 0% to 30% and most preferably from 1 5% to 25%.
- the volatile vehicle is chosen so that urea is precipitated in the presence of the volatile vehicle.
- the volatile vehicle evaporates and the urea becomes dissolved in the remaining components.
- the volatile vehicle has a vapor pressure of more than 1 kPa at 25°C.
- the volatile vehicle should be pharmaceutically acceptable.
- a non-limiting list of suitable compounds for the volatile vehicle includes ethyl acetate and butyl acetate and mixtures thereof. When a mixture of ethyl acetate and butyl acetate is used, the weight ratio of ethyl acetate to butyl acetate is preferably from 3 : 1 to 1 : 1 , most preferably about 2: 1 .
- the amount of volatile vehicle is preferably from 60% to 95%, more preferably from 70% to 90% and most preferably from 75% to 85%.
- the diol is preferably present in concentrations from 2% to 36%, more preferably from 2.5% to 32%, even more preferably from 3% to 30% and most preferably from 6% to 28%.
- the lactic acid or ester thereof is preferably present in concentrations from 0.05% to 1 2%, more preferably from 0.25% to 8%, even more preferably 0.25% to 6% and most preferably from 0.25% to 4%.
- Urea is preferably present in concentrations from 0.
- 1 % to 1 2% more preferably from 0.5% to 1 0%, even more preferably from 0.5% to 8%, even more preferably from 1 % to 6% And most preferably from 1 % to 4%, while the volatile vehicle is preferably present in concentrations from 55% to 95%, more preferably from 60% to 95%, more preferably from 70% to 90%, more preferably from 75% to 85%, even more preferably from 77% to 83% and most preferably from 78 to 82%.
- composition may include additional components well known to a person skilled in the art which are pharmaceutically acceptable.
- a pharmaceutically acceptable gelling agent or thickener preferably selected from the group of gelling or thickening agents that are soluble in the preferred volatile vehicle, e.g. ethyl acetate and butyl acetate.
- gelling or thickening agents are carbomers, carboxyethylene or polyacrylic acids such as carbomer 980 or 940 NF, 981 or 941 NF, 1 382 or 1 342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971 P NF, 974P NF and carbomer derivatives;
- cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC), ethyl-hydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), etc; natural gums such as arabic, xanthan, guar gums, alginates, etc; polyvinylpyrrolidone derivatives; polyoxyethylene polyoxypropylene copolymers, etc; others like chitin, chitosan, polyvinyl alcohols, pectins, veegum grades, and the like.
- suitable thickeners are represented by methacrylates exemplified by but not limited to different types of Eudragit.
- gelling agents or viscosants known by those skilled in the art may also be used.
- a preferred group of thickeners is polymethacrylates (copolymers derived from esters of acrylic and methacrylic acids).
- other gelling agents or viscosants known by those skilled in the art may also be used.
- the gelling agent or thickener is present from about 0.2% to about 20% depending on the type of polymer, as known by one skilled in the art.
- the gelling agent or thickener which suitably is a polymethacrylate, is present at a concentration of from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0%.
- the gelling agent or thickener is selected so that the composition, when applied on a nail, forms a film within a reasonable time, such as within 1 0 minutes, preferably within 5 minutes, more preferably within 2 minutes, more preferably within 1 minute.
- a reasonable time such as within 1 0 minutes, preferably within 5 minutes, more preferably within 2 minutes, more preferably within 1 minute.
- the film is not formed within a shorter time than 30 seconds.
- the gelling agent or thickener preferably forms a film so that the non-evaporating components of the composition remain on the application site.
- the composition may comprise a pharmaceutically acceptable base, preferably sodium hydroxide.
- a pharmaceutically acceptable base preferably sodium hydroxide.
- the base which preferably is sodium hydroxide, is present in a concentration of from 0.01 % to 0.8%, more suitably 0.05% to 0.6%, even more suitably from 0. 1 % to 0.4%.
- the water content of the composition depends on the selection of the included compounds.
- the composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide.
- the water content may be from 0. 1 % to 1 %, more preferably from 0.2% to 0.4%.
- the composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide.
- the water content may be from 0. 1 % to 1 %, more preferably from 0.2% to 0.4%.
- the composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide.
- the water content may be from 0. 1 % to 1 %, more preferably from 0.2% to 0.4%.
- the composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide.
- the water content may be from 0. 1 % to 1 %, more preferably from 0.2% to 0.4%.
- the composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide.
- the water content may be from 0. 1 % to 1 %
- composition may include no added water. Nevertheless, the composition may then still include water contained in the excipients. For example, various commercially available qualities of lactic acid may contain water. Alternatively, the composition does not contain water.
- composition may further comprise pharmaceutically acceptable buffers such as carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, tartaric acid, diethylamine, triethylamine, diisopropylamine or aminomethylamine.
- buffers such as carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, tartaric acid, diethylamine, triethylamine, diisopropylamine or aminomethylamine.
- buffers such as carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, tartaric acid, diethylamine, triethylamine, diisopropylamine or aminomethylamine.
- other buffers as known in the art may be included.
- the composition can be prepared with pharmaceutically acceptable chelating agents exemplified by, but not limited to, EDTA or its derivatives and phosphonic acids.
- concentration of EDTA is suitably from 0. 1 % to 1 %, even more suitably from 0.3% to 0.7% and most preferably from 0.45% to 0.65%.
- the composition may further comprise a pharmaceutically acceptable surfactant.
- the surfactant is selected so that suitable flocculation of the suspended urea particles occurs.
- the surfactant is preferably polar and is soluble in the volatile vehicle and should be able to wet the urea particles. Examples of suitable surfactants can be found in Handbook of Pharmaceutical Excipients
- the concentration of the surfactant is preferably from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6%.
- a preferred surfactant is polysorbate (Tween), in particular polysorbate 80 (Tween 80).
- the non-evaporating components that is, the components that remain on the nail after evaporation of the volatile vehicle, can be washed away using only water or soap and water. This property is referred to as
- washability herein .
- agents that improve the water miscibility and/or solubility of the non-evaporating components may be included in the composition.
- Glycerol is an example of such an agent.
- the concentration of glycerol is suitable from 1 % to 5%
- the composition comprises from 2% to 36%, more preferably from 2.5% to 32%, and most preferably from 3% to 30% of a diol which preferably is propylene glycol; from 0.05% to 1 2%, more preferably from 0.25% to 8% and more preferably from 0.25% to 6% and most preferably from 0.25% to 4% of lactic acid; from 0.
- 1 % to 1 2% more preferably 0.5% to 1 0%, more preferably from 0.5% to 8% and most preferably from 1 % to 6% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0. 1 % to 1 %, preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA; from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0% of a gelling agent or thickener, from 0.
- a surfactant which preferably is polysorbate 80
- 0. 1 % to 1 % preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA
- the composition consists of from 2% to 36%, more preferably from 2.5% to 32%, and most preferably from 3% to 30% of a diol which preferably is propylene glycol; from 0.05% to 1 2%, more preferably from 0.25% to 8% and more preferably from 0.25% to 6% and most preferably from 0.25% to 4% of lactic acid; from 0.
- 1 % to 1 2% more preferably 0.5% to 1 0%, more preferably from 0.5% to 8% and most preferably from 1 % to 6% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0. 1 % to 1 %, preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA; from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0% of a gelling agent or thickener, from 0. 1 % to 1 %, more preferably from 0.2% to 0.4% of water and from 0.01 % to 0.8%, more preferably 0.05% to 0.6%, even more preferably from 0. 1 % to 0.4% of NaOH, the remainder of the following components: from 0.05% to 1
- composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
- composition includes urea, lactic acid or an ester thereof, a diol and a volatile vehicle and may in addition include other pharmaceutically
- the composition may consist of urea, a diol, lactic acid, a volatile vehicle and a gelling agent or thickener.
- the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and a chelating agent.
- the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a chelating agent and a surfactant.
- the composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a chelating agent, a surfactant and water.
- the composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a surfactant and water.
- the composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and water.
- the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, water and chelating agent.
- the composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and a surfactant.
- One preferred composition comprises from 5% to 1 0%, more preferably from 6% to 8% of a diol, from 0.5% to 2%, more preferably from 0.75% to 1 .5% of lactic acid, from 1 .5% to 3%, more preferably 1 .8% to 2.5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
- a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
- a preferred composition consists of from 5% to 1 0%, more preferably from 6% to 8% of a diol which preferably is propylene glycol; from 0.5% to 2%, more preferably from 0.75% to 1 .5% of lactic acid; from 1 .5% to 3%, more preferably 1 .8% to 2.5% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0.
- a chelating agent which preferably is EDTA
- composition may be prepared with higher concentrations of urea, lactic acid and diol as follows.
- a preferred composition with a higher proportion of urea, lactic acid and diol comprises from 1 0% to 20%, more preferably from 1 2% to 1 6% of propylene glycol, from 1 % to 4%, more preferably from 1 .5% to 3% of lactic acid, from 3% to 6%, more preferably from 3.6% to 5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
- a preferred composition comprises about 1 4% propylene glycol, about 2% lactic acid, about 4% urea and the remainder, preferably about 80% of a volatile vehicle, which preferably is ethyl acetate, butyl acetate, or a mixture of butyl acetate and ethyl acetate.
- a preferred composition with a even higher proportion of urea, lactic acid and diol comprises from 1 5% to 30%, more preferably from 1 8% to 25% of propylene glycol, from 1 .5% to 6%, more preferably from 2.25% to 4.4% of lactic acid, from 4.5% to 9%, more preferably 5.4% to 7.5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
- the composition When used on a nail, the composition is suitably applied and the volatile vehicle is allowed to evaporate. The urea then dissolves in the remainder of the composition (the solvent comprising a diol and lactic acid). The urea is then able to penetrate into the keratinous layer of the nail.
- composition on the infected nail suitably takes place at least once a week, more preferably once every two days, and even more preferably once daily.
- a composition according to the invention for the treatment of a fungal infection of a nail and the use of a composition according to the invention for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
- the propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension.
- the propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate/butyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension.
- Propylene glycol was weighed into a beaker. 1 0 M sodium hydroxide (when present) was added to the propylene glycol and the mixture was allowed to stir with a magnetic stir bar for 5 min. Lactic acid was dissolved into the propylene glycol and urea was then added. After the urea had dissolved, polysorbate 80 was added. The solution was stirred for 5 min and optionally EDTA was added. In a separate flask, the polymethacrylate polymer Eudragit ® RS PO (Evonik Industries) was dissolved in ethyl acetate and/or butyl acetate.
- Example 6A Batch size 1 00 g.
- composition was manufactured by dissolving propylene glycol, urea, NaOH, water and lactic acid and an antifungal in one vessel and the remaining compounds in ethyl acetate in another vessel.
- the suspension was stored at 2°-8°, 25°, 30° and 40°C for up to 1 2 months and analysis of urea content demonstrated that the invented formulation is stable at the tested temperatures.
- the urea concentration after storage is shown in Table 1 . The fact that the concentration appears to be higher can be explained by an acceptable error in the method.
- the testing conditions comply with drug regulatory requirements (ICH).
- Storage assays was carried out in a GMP unit. The assay for urea was performed with an HPLC method.
- the stability data show that the urea content is within 1 .8 and 2.2 %, which is 2% ⁇ 1 0%. Thus, it can be concluded that the urea is stable in the composition.
- the presence of an antifungal component is not expected to influence the stability of urea.
- An important property of a formulation intended for the nail is its ability to deliver the medically or cosmetically useful substance to the nail. This can be studied in vitro using human cadaver nails or bovine hoof material. The advantage of the bovine hoof material is that penetration of most compounds is much faster than through nail.
- the thickness of the membranes were 1 00 ⁇ and they were prepared by gluing 3 *3 cm cubes of the hoof sole to a methacrylate block and making slices of 1 00 ⁇ thickness with a dermatome.
- the hoof membranes were frozen and stored at -80°C until use.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition for topical application on a nail comprising urea, a diol and lactic acid or an ester thereof and a volatile vehicle characterized in that urea is soluble in the solvent in the absence of the volatile vehicle, and that urea is in the solid state in the solvent in the presence of the volatile vehicle. Furthermore, a method for the stabilization of urea in a liquid formulation is shown.
Description
NOVEL COMPOSITION FOR TOPICAL USE ON A NAIL
Technical field
[0001 ] The present invention generally relates to novel compositions comprising urea for topical application on nails.
Background
[0002] Urea is a useful agent for the treatment of several skin conditions and is often included in formulations for the treatment of nails. Urea can also be used as a penetration enhancer in formulations for skin and can be included in formulations for the treatment of nails.
[0003] Several patent applications teach the possibility of increasing penetration of an active pharmaceutical ingredient through skin by evaporation of solvents. For example US2007/01 96453 (Zars Inc, Zhang Jie et al.) concerns adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux- enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system . When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. The application mention the use of urea for the treatment of warts.
[0004] Previously, formulations comprising urea, lactic acid and a diol are known . WO87/0461 7 describes such a formulation for the treatment of skin and fungal infections of the nail. However, the current shelf life of that formulation is
limited to about two years. The reason for this is that urea is unstable - degrading over time resulting in the loss of activity of the product. This is a major obstacle to achieving cost-efficient production as new batches of the product have to be produced frequently.
[0005] The major degradation products of urea are carbon dioxide and ammonia. Factors that promote the degradation process include light, heat and the presence of certain enzymes.
[0006] Because of the short shelf-life, there is a need for novel stable
formulations comprising urea.
[0007] Moreover, a general problem when treating fungal infections of the nail is to achieve sufficient penetration of the pharmaceutical composition to and into the keratin layer of the nail. Dermatological formulations for application on the nail must therefore be designed in such a way that maximum penetration is achieved.
Definitions
[0008] The term "about" is used to indicate a deviation +/- 1 0% of the stated value, where applicable. By way of example, "about 20%" denotes a value of from 1 8% to 22%.
[0009] The term "soluble" refers the ability of the solvent to dissolve an amount of the active pharmaceutical ingredient that is relevant for its pharmacological effect.
[001 0] As used herein, unless stated otherwise, the amounts of components in percent refer to percent by weight and are based on the total weight of the composition .
[001 1 ] Before the present invention is described, it is to be understood that the terminology employed herein is used for the purpose of describing particular
embodiments only and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims and equivalents thereof.
Summary
[001 2] It is an object of the invention to address the problem of urea stability mentioned above. It would be desirable to have a composition for topical application on nails where urea has an increased stability.
[001 3] Therefore it is provided, in a first general aspect of the invention, a urea-comprising composition for topical application on a nail comprising urea, a diol, lactic acid or an ester thereof, and a volatile vehicle, characterized in that urea is soluble in the composition in the absence of the volatile vehicle, and that urea is in the solid state in the composition in the presence of the volatile vehicle.
[001 4] The composition is intended for cosmetic and/or pharmaceutical use on discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
[001 5] The invention presents a novel way to maximize the chemical activity of urea and thereby the penetration rate through nail and preserving the urea so that it is not degraded. The inventive formulations and method minimizes the chemical degradation of urea as the whole composition contains very little water and the urea is in the solid state. Furthermore, the invention also results in an increased concentration of urea on the application site when the volatile vehicle evaporates, thereby facilitating penetration. This results in higher penetration of urea.
[001 6] One important advantage of the present invention is that the
composition will have a high stability and therefore a long shelf life. The longer
shelf-life increases cost-efficiency, as larger batches can be produced, distributed and stored.
[001 7] Another advantage is that, because the urea component is stable, the composition will contain a low amount of degradation products when it is used by the consumer.
[001 8] Yet another advantage is that the formulation lacks an antifungal agent, in particular an antifungal agent with strong antifungal activity. This enables the production and sale of a non-prescription product and/or over the counter product.
[001 9] Thus, the composition does not comprise an antifungal agent selected among imidazoles, triazoles, thiazoles, allylamines, and echinocandins examples of which are miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole,
voriconazole, terconazole, abafungin, terbinafine, amorolfine, naftifine, butenafine, anidulafungin, caspofungin, and micafungin .
[0020] In particular, the lactic acid or ester thereof may be lactic acid. The diol in the composition is preferably propylene glycol.
[002 1 ] Preferably, the volatile vehicle comprises, consists essentially of, or consists of, at least one selected from the group consisting of ethyl acetate and butyl acetate and mixtures of ethyl acetate and butyl acetate.
[0022] One suitable composition comprises from 2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof and from 0.5% to 8% of urea and from 55% to 95% of a volatile vehicle.
[0023] Another suitable composition comprises from 2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof, from 0.5% to 8% of urea; the
remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate, and optionally, other components selected from the group consisting of a gelling agent or thickener, a surfactant, a chelating agent, sodium hydroxide, water and glycerol.
[0024] Yet another suitable composition consist- or consist essentially of - from 2.5% to 32% of propylene glycol, from 0.25% to 6% of lactic acid, from 0.5% to 8% of urea, from 0.05% to 1 .5% of a surfactant; from 0. 1 % to 1 % of a chelating agent, from 2% to 1 6% of a gelling agent or thickener, from 0.01 % to 0.8% of sodium hydroxide and from 0. 1 % to 1 % of water and from 1 % to 5% of glycerol; the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
[0025] In a second general aspect of the invention there is provided a composition for use in the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
[0026] In a third general aspect of the invention there is provided use of a composition according to the invention for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
[0027] In a fourth general aspect of the invention there is provided a method for increasing the stability of urea. The method comprises the steps of dissolving urea in a solvent comprising a diol and lactic acid and adding a volatile vehicle which precipitates the urea.
[0028] In a fifth general aspect of the invention there is provided a method for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis, comprising the step of topically administering a composition according to the invention on a nail. The method
comprises the steps of applying the inventive composition to a nail, allowing the volatile vehicle to evaporate so that urea dissolves in the remaining solvents, and leaving the composition on the nail and allowing the urea exert its function.
Preferably, the amount of urea present in the composition after evaporation of the volatile vehicle is from 2% to 30%. Preferably, the application is carried out at least once a week.
[0029] Yet another aspect of the invention is a composition comprising a precipitation or suspension of urea obtainable according to the method described herein .
Detailed Description
[0030] In the following, a detailed description of the invention will be provided.
[003 1 ] The composition comprises a suspension of urea particles in a solvent comprising a diol and lactic acid or an ester thereof and a volatile vehicle that precipitates urea. The solvent has a lower vapor pressure than the volatile vehicle such that the composition comprises a suspension of urea particles during storage when the volatile vehicle is present. When the composition is applied to a nail the volatile vehicle evaporates. The urea the dissolves in the remaining components (mainly lactic acid and a diol), so that it becomes accessible for penetration into the nail.
[0032] Preferably, at least 30%, more preferably at least 50%, more preferably at least 60% and most preferably at least 70% of the urea is solu the composition in the absence of the volatile vehicle.
[0033] The composition includes lactic acid or an ester thereof. Suitable esters of lactic acid include butyl lactate and ethyl lactate. Mixtures of two or more of lactic acid, butyl lactate and ethyl lactate are also suitable.
[0034] The disclosed formulation allows high penetration of urea to, through and into the nail.
[0035] Preferably, at least 5%, more preferably at least 1 0%, more preferably at least 20%, more preferably 30%, more preferably 40% more preferably 50%, more preferably 60 %, more preferably 80% and most preferably at least 95% of the urea is in the solid state in the presence of the volatile vehicle at a temperature from 2°C to 25°C.
[0036] The composition does not comprise an antifungal agent, that is, a compound with strong antifungal activity. A list of such antifungals can be found in Goodman & Gilmans The pharmacological basis of therapeutics, 2001 , 1 295- 1 3 1 2, McGraw-Hill. In particular, the composition does not comprise imidazoles, such as miconazole, ketoconazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazoles, such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, and terconazole; thiazoles, such as abafungin; allylamines, such as terbinafine, amorolfine, naftifine, and butenafine; and echinocandins, such as anidulafungin, caspofungin, and micafungin .
[0037] Furthermore, the composition does not comprise polyenes or miscellaneous compounds such as griseofulvin, benzoic, salicylic, propionic, undecylenic or caprylic acid, or clotimtrazole, potassium iodide, tolnaphtate, ciclopirox olamine, amphotercin C, nystatin, flucytosine, or haloprogine.
[0038] Thus, one further advantage is that the formulation lacks an antifungal agent with strong antifungal activity. This enables the production and marketing of a
product that can be sold as a non-prescription and/or over-the-counter product. Furthermore, the use of antifungal drugs will cause antifungal agents to be released to the environment. The use of antifungals may result in the development of resistance to these drugs which would result in reduced efficacy of available treatment. One further aspect is that antifungal drugs are expensive to produce and handle. All of these drawbacks are avoided by excluding an antifungal drug.
[0039] The amount of urea present in the invented composition after evaporation of the volatile vehicle is in the range of from 2% to 40%, more preferably from 2% to 30%. The amount of diol, preferably propylene glycol, in the composition after evaporation of the volatile part is preferably from 40% to 90%. These concentrations are suitable for the treatment of fungal infection of nails and the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
[0040] The composition comprises a diol, of which in particular propylene glycol is suitable. Other suitable diols are butanediol, pentanediol and hexanediol.
[0041 ] The combined amount of urea, diol and lactic acid in the composition is preferably from about 5% to about 40% of the total composition, more preferably from 1 0% to 30% and most preferably from 1 5% to 25%.
[0042] The volatile vehicle is chosen so that urea is precipitated in the presence of the volatile vehicle. When the composition is applied on a nail the volatile vehicle evaporates and the urea becomes dissolved in the remaining components.
[0043] Suitably the volatile vehicle has a vapor pressure of more than 1 kPa at 25°C. The volatile vehicle should be pharmaceutically acceptable.
[0044] A non-limiting list of suitable compounds for the volatile vehicle includes ethyl acetate and butyl acetate and mixtures thereof. When a mixture of ethyl acetate and butyl acetate is used, the weight ratio of ethyl acetate to butyl acetate is preferably from 3 : 1 to 1 : 1 , most preferably about 2: 1 . The amount of volatile vehicle is preferably from 60% to 95%, more preferably from 70% to 90% and most preferably from 75% to 85%.
[0045] The diol is preferably present in concentrations from 2% to 36%, more preferably from 2.5% to 32%, even more preferably from 3% to 30% and most preferably from 6% to 28%. The lactic acid or ester thereof is preferably present in concentrations from 0.05% to 1 2%, more preferably from 0.25% to 8%, even more preferably 0.25% to 6% and most preferably from 0.25% to 4%. Urea is preferably present in concentrations from 0. 1 % to 1 2%, more preferably from 0.5% to 1 0%, even more preferably from 0.5% to 8%, even more preferably from 1 % to 6% And most preferably from 1 % to 4%, while the volatile vehicle is preferably present in concentrations from 55% to 95%, more preferably from 60% to 95%, more preferably from 70% to 90%, more preferably from 75% to 85%, even more preferably from 77% to 83% and most preferably from 78 to 82%.
[0046] In addition, the composition may include additional components well known to a person skilled in the art which are pharmaceutically acceptable.
[0047] In order to modify the viscosity of the composition it may comprise a pharmaceutically acceptable gelling agent or thickener, preferably selected from the group of gelling or thickening agents that are soluble in the preferred volatile vehicle, e.g. ethyl acetate and butyl acetate. Non-limiting examples of such gelling or thickening agents are carbomers, carboxyethylene or polyacrylic acids such as carbomer 980 or 940 NF, 981 or 941 NF, 1 382 or 1 342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971 P NF, 974P NF and carbomer derivatives;
cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC),
ethyl-hydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), etc; natural gums such as arabic, xanthan, guar gums, alginates, etc; polyvinylpyrrolidone derivatives; polyoxyethylene polyoxypropylene copolymers, etc; others like chitin, chitosan, polyvinyl alcohols, pectins, veegum grades, and the like. Yet other suitable thickeners are represented by methacrylates exemplified by but not limited to different types of Eudragit. Alternatively, other gelling agents or viscosants known by those skilled in the art may also be used. A preferred group of thickeners is polymethacrylates (copolymers derived from esters of acrylic and methacrylic acids). Alternatively, other gelling agents or viscosants known by those skilled in the art may also be used.
[0048] The gelling agent or thickener is present from about 0.2% to about 20% depending on the type of polymer, as known by one skilled in the art. Preferably, the gelling agent or thickener, which suitably is a polymethacrylate, is present at a concentration of from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0%.
[0049] Preferably, the gelling agent or thickener is selected so that the composition, when applied on a nail, forms a film within a reasonable time, such as within 1 0 minutes, preferably within 5 minutes, more preferably within 2 minutes, more preferably within 1 minute. Preferably the film is not formed within a shorter time than 30 seconds.
[0050] Furthermore, the gelling agent or thickener preferably forms a film so that the non-evaporating components of the composition remain on the application site.
[005 1 ] The composition may comprise a pharmaceutically acceptable base, preferably sodium hydroxide. Suitably the base, which preferably is sodium
hydroxide, is present in a concentration of from 0.01 % to 0.8%, more suitably 0.05% to 0.6%, even more suitably from 0. 1 % to 0.4%.
[0052] The water content of the composition depends on the selection of the included compounds. The composition may include small amounts of added water in order to enable the inclusion of sodium hydroxide. The water content may be from 0. 1 % to 1 %, more preferably from 0.2% to 0.4%. Alternatively, the
composition may include no added water. Nevertheless, the composition may then still include water contained in the excipients. For example, various commercially available qualities of lactic acid may contain water. Alternatively, the composition does not contain water.
[0053] Also the composition may further comprise pharmaceutically acceptable buffers such as carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, tartaric acid, diethylamine, triethylamine, diisopropylamine or aminomethylamine. However, other buffers, as known in the art may be included.
[0054] The composition can be prepared with pharmaceutically acceptable chelating agents exemplified by, but not limited to, EDTA or its derivatives and phosphonic acids. The concentration of EDTA is suitably from 0. 1 % to 1 %, even more suitably from 0.3% to 0.7% and most preferably from 0.45% to 0.65%.
[0055] Preferably, the composition may further comprise a pharmaceutically acceptable surfactant. The surfactant is selected so that suitable flocculation of the suspended urea particles occurs. The surfactant is preferably polar and is soluble in the volatile vehicle and should be able to wet the urea particles. Examples of suitable surfactants can be found in Handbook of Pharmaceutical Excipients
Pharmaceutical Press 6th edition, 2009, and the most suitable surfactants for the system can selected by a person skilled in the art. The concentration of the surfactant is preferably from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6%. A preferred surfactant is polysorbate (Tween), in
particular polysorbate 80 (Tween 80). One advantage with adding a surfactant is to achieve suitable flocculation of the suspended particles in order to prevent caking of the suspension .
[0056] Preferably, the non-evaporating components, that is, the components that remain on the nail after evaporation of the volatile vehicle, can be washed away using only water or soap and water. This property is referred to as
"washability" herein . In order to improve the washability, agents that improve the water miscibility and/or solubility of the non-evaporating components may be included in the composition. Glycerol is an example of such an agent. The concentration of glycerol is suitable from 1 % to 5%
[0057] The following are non-limiting examples of compositions.
[0058] In general the composition comprises from 2% to 36%, more preferably from 2.5% to 32%, and most preferably from 3% to 30% of a diol which preferably is propylene glycol; from 0.05% to 1 2%, more preferably from 0.25% to 8% and more preferably from 0.25% to 6% and most preferably from 0.25% to 4% of lactic acid; from 0. 1 % to 1 2%, more preferably 0.5% to 1 0%, more preferably from 0.5% to 8% and most preferably from 1 % to 6% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0. 1 % to 1 %, preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA; from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0% of a gelling agent or thickener, from 0. 1 % to 1 %, more preferably from 0.2% to 0.4% of water and from 0.01 % to 0.8%, more preferably 0.05% to 0.6%, even more preferably from 0. 1 % to 0.4% of NaOH, the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
[0059] Thus, in general the composition consists of from 2% to 36%, more preferably from 2.5% to 32%, and most preferably from 3% to 30% of a diol which preferably is propylene glycol; from 0.05% to 1 2%, more preferably from 0.25% to 8% and more preferably from 0.25% to 6% and most preferably from 0.25% to 4% of lactic acid; from 0. 1 % to 1 2%, more preferably 0.5% to 1 0%, more preferably from 0.5% to 8% and most preferably from 1 % to 6% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0. 1 % to 1 %, preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA; from 2% to 1 6%, more preferably from 3 % to 1 2%, even more preferably from 4% to 1 0% of a gelling agent or thickener, from 0. 1 % to 1 %, more preferably from 0.2% to 0.4% of water and from 0.01 % to 0.8%, more preferably 0.05% to 0.6%, even more preferably from 0. 1 % to 0.4% of NaOH, the remainder of the
composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
[0060] The composition includes urea, lactic acid or an ester thereof, a diol and a volatile vehicle and may in addition include other pharmaceutically
acceptable excipients. Thus, the composition may consist of urea, a diol, lactic acid, a volatile vehicle and a gelling agent or thickener.
[0061 ] Alternatively, the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and a chelating agent.
[0062] Also, the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a chelating agent and a surfactant.
[0063] Furthermore, the composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a chelating agent, a surfactant and water.
[0064] The composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, a surfactant and water.
[0065] The composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and water.
[0066] Also, the composition may consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener, water and chelating agent.
[0067] The composition may also consist of urea, a diol, lactic acid, a volatile vehicle, a gelling agent or thickener and a surfactant.
[0068] One preferred composition comprises from 5% to 1 0%, more preferably from 6% to 8% of a diol, from 0.5% to 2%, more preferably from 0.75% to 1 .5% of lactic acid, from 1 .5% to 3%, more preferably 1 .8% to 2.5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
[0069] A preferred composition consists of from 5% to 1 0%, more preferably from 6% to 8% of a diol which preferably is propylene glycol; from 0.5% to 2%, more preferably from 0.75% to 1 .5% of lactic acid; from 1 .5% to 3%, more preferably 1 .8% to 2.5% of urea; and optionally one or more of the following components: from 0.05% to 1 .5%, more preferably from 0.25% to 0.75% and most preferably from 0.4% to 0.6% of a surfactant which preferably is polysorbate 80; from 0. 1 % to 1 %, preferably 0.3% to 0.7% and most preferably from 0.45% to 0.65% of a chelating agent, which preferably is EDTA; from 2% to 1 6%, more preferably from 3% to 1 2%, even more preferably from 4% to 1 0% of a gelling agent or thickener, from 0. 1 % to 1 %, more preferably from 0.2% to 0.4% of water and from 0.01 % to 0.8%, more preferably from 0.05% to 0.6%, even more
preferably from 0. 1 % to 0.4% of NaOH, the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
[0070] However, it may be suitable to increase the concentration of urea, lactic acid and diol while keeping the ratio of the concentrations of these
compounds constant.
[0071 ] Thus, a composition may be prepared with higher concentrations of urea, lactic acid and diol as follows.
[0072] Thus, a preferred composition with a higher proportion of urea, lactic acid and diol comprises from 1 0% to 20%, more preferably from 1 2% to 1 6% of propylene glycol, from 1 % to 4%, more preferably from 1 .5% to 3% of lactic acid, from 3% to 6%, more preferably from 3.6% to 5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
[0073] A preferred composition comprises about 1 4% propylene glycol, about 2% lactic acid, about 4% urea and the remainder, preferably about 80% of a volatile vehicle, which preferably is ethyl acetate, butyl acetate, or a mixture of butyl acetate and ethyl acetate.
[0074] A preferred composition with a even higher proportion of urea, lactic acid and diol comprises from 1 5% to 30%, more preferably from 1 8% to 25% of propylene glycol, from 1 .5% to 6%, more preferably from 2.25% to 4.4% of lactic acid, from 4.5% to 9%, more preferably 5.4% to 7.5% urea, and optionally other components, such as, for example, a gelling agent or thickener in the amounts described herein, the remainder being ethyl acetate or butyl acetate or a mixture of ethyl acetate and butyl acetate.
[0075] When used on a nail, the composition is suitably applied and the volatile vehicle is allowed to evaporate. The urea then dissolves in the remainder of the composition (the solvent comprising a diol and lactic acid). The urea is then able to penetrate into the keratinous layer of the nail.
[0076] Application of the composition on the infected nail suitably takes place at least once a week, more preferably once every two days, and even more preferably once daily. Thus, there is also provided the use of a composition according to the invention for the treatment of a fungal infection of a nail and the use of a composition according to the invention for the treatment of discolored, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
EXAMPLES
Example 1
[0077] 9.96 g of propylene glycol was weighed into a 1 00 ml beaker. 0.54 g of 1 0 M sodium hydroxide was added to the propylene glycol and the mixture was allowed to stir with a magnetic stir bar for 5 min . 1 .5 g of lactic acid was dissolved before 3.0 g of urea was added. After the urea had dissolved, 0.75 g of polysorbate 80 was added and the solution was stirred for 5 min before the addition 0.075 g of EDTA. In a separate flask 1 3.5 g of the polymethacrylate polymer Eudragit® RS PO (Evonik Industries) was dissolved in a mixture of 93 ml of ethyl acetate and 41 ml of butyl acetate.
The resulting composition was as foil
Propylene glycol 6.67%
Sodium hydroxide 10M 0.36%
Lactic acid 1.00%
Urea 2.01%
Polysorbate 80 0.50%
EDTA 0.05%
Eudragit SPO 9.04%
Ethyl acetate 56.19%
Butyl acetate 24.17%
Total 100.00%
[0078] The propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate/butyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a
consequence of the precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension.
Example 2
[0079] 9.96 g of propylene glycol was weighed into a 1 00 ml beaker. 0.56 g of 1 0 M sodium hydroxide was added to the propylene glycol and the mixture was stirred with a magnetic stir bar for 5 min. 1 .50 g of lactic acid was dissolved before 3.00 g of urea was added. After the urea had dissolved 0.75 g of polysorbate 80 was added and the solution was stirred for 5 min before the addition 0.075 g of EDTA. In a separate flask, 1 3.5 g of the polymethacrylate polymer Eudragit® RS PO (Evonik Industries) was dissolved in a mixture of 66.5 ml of ethyl acetate and 68 ml of butyl acetate.
[0080] The resulting composition was as follows:
Propylene glycol 6.68%
Sodium hydroxide 10M 0.38%
Lactic acid 1.01%
Urea 2.01%
Polysorbate 80 0.50%
EDTA 0.05%
Eudragit SPO 9.05%
Ethyl acetate 40.21%
Butyl acetate 40.12%
Total 100.00%
[0081 ] The propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate/butyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a
consequence of the precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension .
Example 3
[0082] 9.96 g of propylene glycol as weighed into a 1 00 ml beaker. 0.55 g of 1 0 M sodium hydroxide was added to the propylene glycol, and the mixture was allowed to stir with a magnetic stir bar for 5 min . 1 .50 g of lactic acid was dissolved before 3.00 g of urea was added. After the urea had dissolved, 0.75 g of polysorbate 80 was added and the solution was stirred for 5 min before 0.079 g of EDTA was added. In a separate flask, 1 3.5 g of the polymethacrylate polymer Eudragit® RS PO (Evonik Industries) was dissolved in 1 33.8 ml of ethyl acetate.
[0083] The resulting composition was as follows:
Propylene glycol 6.64%
Sodium hydroxide 10M 0.37%
Lactic acid 1.00%
Urea 2.00%
Polysorbate 80 0.50%
EDTA 0.05%
Eudragit SPO 9.00%
Ethyl acetate 80.44%
Butyl acetate 0.00%
Total 100.00%
The propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension.
Example 4
[0084] 9.96 g of propylene glycol as weighed into a 1 00 ml beaker. 0.56 g of 1 0 M sodium hydroxide was added to the propylene glycol, and the mixture was stirred with a magnetic stir bar for 5 min. 1 .50 g of lactic acid was dissolved before 3.00 g of urea was added. After the urea had dissolved, 0.77 g of polysorbate 80 was added and the solution was stirred for 5 min before 0.077 g of EDTA was added. In a separate flask, 1 3.5g of the polymethacrylate polymer Eudragit® RS PO (Evonik Industries) was dissolved in 1 37.2 ml of butyl acetate.
[0085] The resulting composition was as follows:
Propylene glycol 6.64%
Sodium hydroxide 10M 0.37%
Lactic acid 1.00%
Urea 2.00%
Polysorbate 80 0.51%
EDTA 0.05%
Eudragit SPO 8.99%
Ethyl acetate 0.00%
Butyl acetate 80.44%
Total 100.00%
[0086] The propylene glycol solution containing urea was added to the solution containing the polymer in butyl acetate solution . Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of
precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension .
Example 5
[0087] 9.97 g of propylene glycol as weighed into a 1 00 ml beaker. 0.54 g of 1 0 M sodium hydroxide was added to the propylene glycol and the mixture was allowed to stir with a magnetic stir bar for 5 min . 1 .50 g of lactic acid was dissolved before 3.01 g of urea was added. After the urea had dissolved, 0.76 g of polysorbate 80 was added and the solution was stirred for 5 min before 0.080 g of EDTA was added. In a separate flask, 7.5 g of the polymethacrylate polymer
Eudragit ® RS PO (Evonik Industries) was dissolved in 72.3 ml of ethyl acetate and 49.4 ml of butyl acetate.
[0088] The resulting composition was as follows:
Propylene glycol 6.64%
Sodium hydroxide 10M 0.37%
Lactic acid 1.00%
Urea 2.00%
Polysorbate 80 0.50%
EDTA 0.05%
Eudragit SPO 9.00%
Ethyl acetate 60.32%
Butyl acetate 20.12%
Total 100.00%
The propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate/butyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension.
Example 6
[0089] The following procedure was applied for example formulations 6A-6F
[0090] Propylene glycol was weighed into a beaker. 1 0 M sodium hydroxide (when present) was added to the propylene glycol and the mixture was allowed to stir with a magnetic stir bar for 5 min. Lactic acid was dissolved into the propylene glycol and urea was then added. After the urea had dissolved, polysorbate 80 was added. The solution was stirred for 5 min and optionally EDTA was added. In a separate flask, the polymethacrylate polymer Eudragit ® RS PO (Evonik Industries) was dissolved in ethyl acetate and/or butyl acetate.
[0091 ] The propylene glycol solution containing urea was added to the solution containing the polymer in ethyl acetate/butyl acetate solution. Upon addition of the propylene glycol phase, the solution turned opaque as a consequence of precipitation of urea. After sedimentation, the particles formed a loose sediment that was easily shaken to form a suspension .
Example 6A Batch size 1 00 g.
Propylene glycol 1 7.5 g
Lactic acid 5.0 g
Urea 2.5 g
Polysorbate 80 0.3 g
Ethyl acetate 70.7 g
Eudragit RS PO 4.0 g
Example 6B
Batch size 500 g.
Propylene glycol 49.8 g
Lactic acid 7.52 g
Urea 1 5.01 g
Polysorbate 80 2.5 g
Ethyl acetate 382.27g
Eudragit RS PO 40.0 g
EDTA 0.25 g
NaOH 1 0 M 2.7 g
[0092] The percentage of the composition was as follows:
Example 6C
Batch size 150 g.
Propylene glycol 14.94 g
Lactic acid 2.3 g
Urea 4.51g
Polysorbate 80 0.75 g
Ethyl acetate 80.28g
Butyl acetate 34.41g
Eudragit RS PO 12.0g
EDTA 0.078g
NaOH 10 M 0.84 g
[0093] The percentage of the composition was as follows:
Example 6D
Batch size 40 g.
Propylene glycol 8.4 g
Lactic acid 1 -2 g
Urea 2.4 g
Polysorbate 80 0.1 2 g
Ethyl acetate 26.3 g
Eudragit RS 1 .6 g
[0094] The percentage of the composition was as follows:
% (W/W)
Propylene glycol 21 .0
Lactic Acid 6.0
Urea 3.0
Polysorbate 80 0.3
Ethyl acetate 65.7
Eudragit RS PO 4.0
Example 6E
Batch size 40 g .
Lactic Acid 1 .4 g
Propylene glycol 9.8 g
Urea 2.8 g
Polysorbate 80 0. 1 2 g
Ethyl acetate 24.3 g
Eudragit RSPO 1 .6 g
[0095] The percentage of the composition was as foil
% (w/w)
Lactic acid 3.5
Propylene glycol 24.5
Urea 7
Polysorbate 80 0.3
Ethyl acetate 60.7
Eudragit RS PO 4.00
Total 1 00
Example 6F
Batch size 5 g .
Lactic Acid 0.22 g
Propylene glycol 1 .54 g
Urea 0.44 g
Butyl acetate 2.8 g
[0096] The percentage of tta composition was as follows:
% (w/w)
Lactic acid 4.4
Propylene glycol 30.8
Urea 8.8
Butyl acetate 56
Total 1 00
Example 7
[0097] The following composition was manufactured by dissolving propylene glycol, urea, NaOH, water and lactic acid and an antifungal in one vessel and the remaining compounds in ethyl acetate in another vessel.
[0098] When mixing the propylene glycol solution into the ethyl acetate solution a suspension was formed. The suspension was packed in clear glass bottles with a polypropylene cap.
[0099] The suspension was stored at 2°-8°, 25°, 30° and 40°C for up to 1 2 months and analysis of urea content demonstrated that the invented formulation is stable at the tested temperatures. The urea concentration after storage is shown in Table 1 . The fact that the concentration appears to be higher can be explained by an acceptable error in the method. The testing conditions comply with drug regulatory requirements (ICH). Storage assays was carried out in a GMP unit. The assay for urea was performed with an HPLC method.
[001 00] The stability data show that the urea content is within 1 .8 and 2.2 %, which is 2% ± 1 0%. Thus, it can be concluded that the urea is stable in the composition. The presence of an antifungal component is not expected to influence the stability of urea.
Table 1 . Urea stability.
Example 8
[001 01 ] In order to determine the amount of urea present in the solid state, the amount of urea present in the solid phase after centrifugation was determined in the following composition :
Ethyl acetate 90%
Propylene glycol 7%
Urea 2%
Lactic acid 1 %
[001 02] Lactic acid and urea were dissolved in propylene glycol and ethyl acetate was added and a suspension was formed.
[001 03] 5 g of the suspension was centrifuged at 1 5.000 rpm for 60 minutes at 20°C. The supernatant was removed and analysis of the solid phase was made after dissolution and dilution with water. Analysis was performed by HPLC and resulted in a fraction of urea in the solid state of 64.2%. The remainder was either in solution or in colloidal form .
Example 9
[001 04] An important property of a formulation intended for the nail is its ability to deliver the medically or cosmetically useful substance to the nail. This can be studied in vitro using human cadaver nails or bovine hoof material. The advantage of the bovine hoof material is that penetration of most compounds is much faster than through nail.
[001 05] The following composition was used for test of permeability of urea through hoof membranes:
Substance Content (%) (w/w)
Ethyl acetate 48.87
Butyl acetate 32.58
Eudragit RS PO 8.00
EDTA 0.05
Polysorbate 80 0.50
NaOH 0. 1 1
Water 0.25
Lactic acid 1 .00
Propylene glycol 6.64
Urea 2.00
Total % 1 00.00
[001 06] Equipment for the determination of penetration through nail or hoof membranes is commercially available. A Franz cell equipment from PermeGear Inc. (USA) was used (model V9-CB which has 9-station stirrer with black anodized aluminum cell holders for jacketed Franz cells). The glass cells were 9 mm jacketed Franz cells with flat ground joints, a receptor volume of 3 ml, stir-bar and cell top. The temperature in the receptor fluid was set to 32°C. Hoof membranes were collected from bovine hoofs from an abattoir (SLP, Helsingborg, Sweden). Only membranes from the sole of the bovine hoof were used. The thickness of the membranes were 1 00 μηη and they were prepared by gluing 3 *3 cm cubes of the hoof sole to a methacrylate block and making slices of 1 00 μηη thickness with a dermatome. The hoof membranes were frozen and stored at -80°C until use.
[001 07] The samples were prepared by evaporation of weighed amounts of product on filter paper discs to a dry weight of 1 20 to 1 30 mg. The reason for this procedure is that the evaporation in the penetration chamber is slow and the solvents may otherwise interact with the membrane and the receptor fluid.
[001 08] After hydration of the hoof membrane for a suitable time the hoof membranes were mounted in the Franz cells and the evaporated preparations were applied. The experiment was terminated after 6 hours whereupon the amount urea that had penetrated to the receptor fluid was determined by HPLC. After 6 hours, almost half the applied dose, about 45%, had penetrated through the membrane as shown in Table 2. This means that urea, although being in solid form when stored, is readily available when the volatile vehicle has evaporated.
Table 2.
Sample Amount Average penetration, Standard
% of dose of deviation, triplicate experiments triplicates
1 1 23 mg 48.61 % 0.70
2 1 35 mg 42.81 % 3.36
Claims
1 . A composition for topical application on a nail comprising urea, a diol, lactic acid or an ester thereof and a volatile vehicle, characterized in that urea is soluble in the composition in the absence of the volatile vehicle, and that urea is in the solid state in the composition in the presence of the volatile vehicle.
2. The composition according to claim 1 wherein said compostion does not comprise an antifungal agent selected among miconazole, ketoconazole,
econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, and terconazole, abafungin,
terbinafine, amorolfine, naftifine, butenafine, anidulafungin, caspofungin, and micafungin
3. The composition according to claim 1 , wherein said composition does not comprise an antifungal agent selected among imidazoles, triazoles, thiazoles, allylamines, and echinocandins.
4. The composition according to claim 1 , wherein said composition does not comprise an antifungal agent.
5. The composition according to any one of claims 1 to 4 where the lactic acid or ester thereof is lactic acid.
6. The composition according to any one of claims 1 to 5, wherein the volatile vehicle comprises at least one compound selected from the group consisting of ethyl acetate and butyl acetate and mixtures of ethyl acetate and butyl acetate.
7. The composition according to any one of claims 1 to 6, wherein the diol is selected from the group consisting of propylene glycol, butanediol, pentanediol and hexanediol or mixtures thereof.
8. The composition according to claim 7, wherein the diol is propylene glycol.
9. The composition according to any one of the previous claims additionally comprising a base.
1 0. The composition according to claim 9, wherein the base is sodium hydroxide.
1 1 . The composition according to any one of claims 1 to 1 0, comprising from
2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof and from 0.5% to 8% of urea and from 55% to 95% of a volatile vehicle.
1 2. The composition according to claim 1 , comprising from 2.5% to 32% of a diol, from 0.25% to 6% of lactic acid or an ester thereof, from 0.5% to 8% of urea; the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate, and optionally other components selected from the group consisting of a gelling agent or thickener, a surfactant, a chelating agent, sodium hydroxide, water and glycerol.
1 3. The composition according to claim 1 consisting of from 2.5% to 32% of propylene glycol, from 0.25% to 6% of lactic acid, from 0.5% to 8% of urea, from 0.05% to 1 .5% of a surfactant; from 0. 1 % to 1 % of a chelating agent, from 2% to 1 6% of a gelling agent or thickener, from 0.01 % to 0.8% of sodium hydroxide and from 0. 1 % to 1 % of water and from 1 % to 5% of glycerol; the remainder of the composition being ethyl acetate or butyl acetate, or a mixture of ethyl acetate and butyl acetate.
1 4. A method for increasing the stability of urea in a liquid formulation, comprising the steps of a) dissolving urea in a solvent comprising a diol and lactic acid, b) adding a volatile vehicle which precipitates the urea.
1 5. A composition comprising a precipitation or suspension of urea obtainable according to claim 1 4.
1 6. Use of a composition according to any one of claims 1 to 1 3 or claim 1 5 for the treatment of fungal infection of the nail.
1 7. Use of a composition according to any of claims 1 to 1 3 or claim 1 5 for the treatment of discoloured, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis.
1 8. A method for treating discoloured, deformed, thick, brittle and/or crumbly nails or nails suffering from infection, trauma or psoriasis comprising the steps of a) applying a composition according to any one of claims 1 to 1 3 or claim 1 5, b) allowing the volatile vehicle to evaporate so that urea dissolves in the remaining solvents, and c) leaving the composition on the nail and allowing the urea to exert its function.
1 9. The method according to claim 1 8 where the amount of urea present in the composition after evaporation of the volatile vehicle is from 2% to 30%.
20. The method according to claim 1 8 or 1 9 where the application is carried out at least once a week.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441346P | 2011-02-10 | 2011-02-10 | |
US61/441,346 | 2011-02-10 | ||
US201161443307P | 2011-02-16 | 2011-02-16 | |
US61/443,307 | 2011-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012110430A1 true WO2012110430A1 (en) | 2012-08-23 |
Family
ID=45567034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/052354 WO2012110430A1 (en) | 2011-02-10 | 2012-02-10 | Novel composition for topical use on a nail |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012110430A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2777689A1 (en) | 2013-03-15 | 2014-09-17 | Moberg Pharma AB | New pharmaceutical composition for the treatment of fungal infections |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004617A1 (en) | 1986-02-04 | 1987-08-13 | Sven Moberg | Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
US20020197291A1 (en) * | 2001-05-30 | 2002-12-26 | Horst Ulbricht | Composition for removing abnormal keratinous material |
US20050181999A1 (en) * | 2002-09-05 | 2005-08-18 | Galderma S.A. | Synergistically pro-penetrating solutions for ungual/peri-ungual dermatological/cosmetic applications |
US20070196453A1 (en) | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs |
DE102006049585A1 (en) * | 2006-10-22 | 2008-04-24 | Susilo, Rudy, Dr. | Nail varnish useful for treating toenail and fingernail disorders comprises urea; fatty acids; allantoin, dexpanthenol, hyaluronic acid, penetration enhancer, antimicrobial agent, antipsoriatic agent and/or antieczema agent |
WO2009085314A1 (en) * | 2008-01-03 | 2009-07-09 | Dow Pharamaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
WO2011019317A1 (en) * | 2009-08-13 | 2011-02-17 | Moberg Derma Ab | Compositions and methods for treating fungal infection of the nail |
-
2012
- 2012-02-10 WO PCT/EP2012/052354 patent/WO2012110430A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004617A1 (en) | 1986-02-04 | 1987-08-13 | Sven Moberg | Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
US20020197291A1 (en) * | 2001-05-30 | 2002-12-26 | Horst Ulbricht | Composition for removing abnormal keratinous material |
US20050181999A1 (en) * | 2002-09-05 | 2005-08-18 | Galderma S.A. | Synergistically pro-penetrating solutions for ungual/peri-ungual dermatological/cosmetic applications |
US20070196453A1 (en) | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs |
DE102006049585A1 (en) * | 2006-10-22 | 2008-04-24 | Susilo, Rudy, Dr. | Nail varnish useful for treating toenail and fingernail disorders comprises urea; fatty acids; allantoin, dexpanthenol, hyaluronic acid, penetration enhancer, antimicrobial agent, antipsoriatic agent and/or antieczema agent |
WO2009085314A1 (en) * | 2008-01-03 | 2009-07-09 | Dow Pharamaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
WO2011019317A1 (en) * | 2009-08-13 | 2011-02-17 | Moberg Derma Ab | Compositions and methods for treating fungal infection of the nail |
Non-Patent Citations (2)
Title |
---|
"Goodman & Gilmans The pharmacological basis of therapeutics", 2001, MCGRAW-HILL, pages: 1295 - 1312 |
"Handbook of Pharmaceutical Excipients", 2009, PHARMACEUTICAL PRESS |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2777689A1 (en) | 2013-03-15 | 2014-09-17 | Moberg Pharma AB | New pharmaceutical composition for the treatment of fungal infections |
WO2014140507A1 (en) * | 2013-03-15 | 2014-09-18 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
WO2014140524A1 (en) | 2013-03-15 | 2014-09-18 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
US8987330B2 (en) | 2013-03-15 | 2015-03-24 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
KR20150054824A (en) * | 2013-03-15 | 2015-05-20 | 모베르그 파르마 아베 | New pharmaceutical composition for the treatment of fungal infections |
EP2777689B1 (en) | 2013-03-15 | 2015-05-27 | Moberg Pharma AB | New pharmaceutical composition for the treatment of fungal infections |
CN104661639A (en) * | 2013-03-15 | 2015-05-27 | 莫贝里制药公司 | New pharmaceutical composition for the treatment of fungal infections |
KR101582448B1 (en) | 2013-03-15 | 2016-01-04 | 모베르그 파르마 아베 | New pharmaceutical composition for the treatment of fungal infections |
US9782372B2 (en) | 2013-03-15 | 2017-10-10 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
CN104661639B (en) * | 2013-03-15 | 2019-06-28 | 莫贝里制药公司 | For treating the new pharmaceutical composition of fungal infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2645058C (en) | Pharmaceutical composition for external use | |
JP5677720B2 (en) | Topical preparation | |
CN111065415A (en) | Platform for local delivery of pharmaceutical agents and method of formulating same | |
JP2009540019A (en) | Topical composition | |
TW200800174A (en) | Pharmaceutical composition for external use | |
US20090182004A1 (en) | Imiquimod formulation | |
TW201609200A (en) | Hydrous adhesive patch | |
TWI468192B (en) | Aqueous patch containing dichlofenac sodium | |
US20120129942A1 (en) | Compositions and methods for treating fungal infection of the nail | |
WO2011070318A2 (en) | Topical formulation | |
JPWO2016068336A1 (en) | Transdermal absorption enhancer and transdermal absorption enhancer | |
WO2008026381A1 (en) | Nail patch | |
US10272054B2 (en) | Topical antifungal compositions | |
WO2012110430A1 (en) | Novel composition for topical use on a nail | |
KR101490708B1 (en) | Composition for transdermal administration comprising loxoprofen or its salt, and transdermal plaster containing same | |
US10588873B2 (en) | Topical antifungal compositions | |
EP3434269B1 (en) | Transdermal absorption-type patch preparation comprising zonisamide | |
RU2457830C2 (en) | Compositions for local application | |
CN117379398A (en) | Guanidine method Xin Tou skin patch and preparation method thereof | |
JPH02152921A (en) | External preparation of percutaneous absorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12702856 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12702856 Country of ref document: EP Kind code of ref document: A1 |